Journal article

Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting

Joris Kleintjens, Xiao Li, Steven Simoens, Vincent Thijs, Marnix Goethals, Ernst R Rietzschel, Yumi Asukai, Omer Saka, Thomas Evers, Petra Faes, Stefaan Vansieleghem, Mimi De Ruyck

PharmacoEconomics | ADIS INT LTD | Published : 2013

Abstract

BACKGROUND: Warfarin, an inexpensive drug that has been available for over half a century, has been the mainstay of anticoagulant therapy for stroke prevention in patients with atrial fibrillation (AF). Recently, rivaroxaban, a novel oral anticoagulant (NOAC) which offers some distinct advantages over warfarin, the standard of care in a world without NOACs, has been introduced and is now recommended by international guidelines. OBJECTIVE: The aim of this study was to evaluate, from a Belgian healthcare payer perspective, the cost-effectiveness of rivaroxaban versus use of warfarin for the treatment of patients with non-valvular AF at moderate to high risk. METHODS: A Markov model was designe..

View full abstract

Grants

Funding Acknowledgements

This study was supported by Bayer HealthCare Pharmaceuticals. Mrs. Mimi De Ruyck, Mrs. Petra Faes, Mr. Stefaan Vansieleghem and Mr. Thomas Evers are employees of Bayer HealthCare Pharmaceuticals. Mrs De Ruyck is the author responsible for the overall content of this publication. Mr. Joris Kleintjens, Mrs. Xiao Li, and Mr. Omer Saka were employees of Deloitte and provided consultant services to Bayer HealthCare. Ms. Yumi Asukai is an employee of IMS Health, which has received consulting fees from Bayer Healthcare. Prof. Steven Simoens, Prof. Vincent Thijs, Prof. Ernst Rietzschel, and Dr. Marnix Goethals acted as consultants to Bayer Healthcare with respect to this study.